Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018

 Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018

Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018

Shots:

  • The presentation includes a collective analysis of 10 research abstracts plus results of OSLER-1 study, assessing Repatha (evolocumab) (420mg) in hypercholesterolemia patients for up to 5 yrs. & an additional RWE of FOURIER study assessing triglycerides in patients with CV risk
  • FOURIER P-III (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) involves assessing of Repatha (140mg SC q2w/420mg monthly) vs PBO with 1EP as CV death & strokes
  • The OSLER-1 study is a part of PROFICIO (Program to Reduce LDL-C and cardiovascular Outcomes Following Inhibition of PCSK9 In different pOpulations) program assessing Repatha in 32 studies in ~ 37,800 patients
  • Repatha is a mAb inhibiting PCSK9 and is approved in >60 countries including the US, Japan, Canada and EU

Click here to read full press release/ article | Ref: Amgen | Image: CNBC

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post